首页 > 市场调查报告书 > 製药

基因治疗学和RNAi 再生医学细胞疗法基因疗法

市场调查报告书

商品编码

1935190

中枢神经系统疾病基因和细胞疗法市场：按治疗方法、适应症和地区划分

Gene and Cell Therapies Targeting CNS Disorders Market, By Therapy Type, By Indication, By Geography

出版日期: 2026年01月12日 | 出版商:

Coherent Market Insights | 英文 151 Pages | 商品交期: 2-3个工作天内

价格

简介目录

2026 年，中枢神经系统疾病的基因和细胞疗法市场规模预计为 79 亿美元，预计到 2033 年将达到 240 亿美元，2026 年至 2033 年的年复合成长率（CAGR）为 16.5%。

报告内容		报告详情
基准年：	2025	2026年市场规模：	79亿美元
历史数据时期：	2020年至2024年	预测期：	2026年至2033年
预测期（2026-2033年）复合年增长率：	16.50%	2033 年的预测值：	240亿美元

目前，市场正经历变革时期，分子生物学、遗传学和再生医学领域的突破性进展正在重新定义中枢神经系统疾病的治疗模式。传统上，由于大脑和脊髓结构的复杂性以及血脑障壁的存在，中枢神经系统疾病的治疗主要以症状治疗为主。然而，基因和细胞疗法克服了这些挑战，实现了标靶治疗、缓解疾病治疗，甚至根治性治疗。

针对中枢神经系统疾病的基因和细胞疗法涵盖了多种复杂的治疗方法，包括基于病毒载体的基因替代疗法、基因静默和编辑技术（包括 CRISPR）、诱导多能干细胞 (iPS 细胞) 衍生的神经前驱细胞以及各种干细胞移植方法。这些治疗方法旨在纠正基因缺陷、恢復神经元功能、替换受损细胞或在分子层面调节疾病路径。神经遗传学和神经生物学的进步促进并加速了该领域的创新，使中枢神经系统疾病成为一个日益引人注目且前景广阔的治疗领域。

帕金森氏症、阿兹海默症、亨丁顿舞蹈症、肌萎缩侧索硬化症和多发性硬化症等神经退化性疾病疾病发病率的不断上升是推动市场成长的关键因素。随着人口老化加剧、诊断技术进步以及公众健康意识的提高，这些疾病的发生率持续上升。

市场动态

由于神经退化性疾病的日益增加以及对缓解疾病治疗方法的迫切需求，中枢神经系统疾病的基因和细胞疗法市场正受到广泛关注。帕金森氏症和阿兹海默症疾病在全球范围内的发病率持续上升，给全球医疗保健系统带来了沉重负担。这推动了人们对能够解决疾病根本原因而非仅仅缓解症状的最先进治疗方案的需求。

技术进步是推动市场未来发展的另一个主要因素，预计将产生重大影响。病毒载体技术（从腺结合病毒（AAV）到慢病毒载体）的进步提高了载体递送至中枢神经系统（CNS）的效率和安全性。同样，干细胞研究领域的进步也促成了功能明确且可规模化生产的干细胞的开发，这些干细胞可用于中枢神经系统移植。

监管环境也正在朝向有利于市场扩张的方向转变。美国食品药物管理局（FDA）和欧洲药品管理局（EMA）等监管机构正日益提供加速核准流程、孤儿药认定以及专门针对先进疗法药品（ATMP）的监管指导。这些倡议缩短了研发週期，为生产商提供了更清晰的指导，从而刺激了中枢神经系统基因和细胞治疗领域的投资和创新。

此外，将人工智慧 (AI) 和数位健康技术应用于中枢神经系统 (CNS) 治疗药物的研发，正在提高临床试验的效率和成功率。机器学习患者分层、数位生物标记和即时疾病监测解决方案，使得试验、终点测量和上市后监测能够更加精准。这是一项至关重要的进展，因为中枢神经系统疾病历来因其复杂性和进展缓慢而难以进行临床评估。

本次调查的主要特点

本报告详细分析了中枢神经系统疾病的基因和细胞疗法市场，以 2025 年为基准年，给出了预测期（2026-2033 年）的市场规模（十亿美元）和复合年增长率（%）。
它重点介绍了各个细分市场的潜在商机，包括治疗方法类型、适应症和地区，并解释了该市场具有吸引力的投资提案矩阵。
该研究深入分析了市场驱动因素、限制因素、机会、技术突破、监管发展、高级临床试验、市场趋势、区域展望以及主要参与者采取的竞争策略。
本报告根据以下参数对中枢神经系统疾病基因和细胞治疗市场的主要企业进行了分析：公司概况、治疗产品线、技术平台、关键发展和策略倡议。
本报告的研究结果将使负责人和经营团队能够就未来的产品发布、治疗方法进步、市场扩张和行销策略做出明智的决策。
这份《中枢神经系统疾病基因和细胞疗法市场》报告的目标受众是业内各类相关人员，包括投资者、供应商、产品製造商、经销商、新参与企业和金融分析师。
相关人员可以透过分析中枢神经系统疾病基因和细胞治疗市场所使用的各种策略矩阵轻鬆做出决策。

北美洲
- 我们
- 加拿大
拉丁美洲
- 巴西
- 阿根廷
- 墨西哥
- 其他拉丁美洲国家
欧洲
- 英国
- 德国
- 义大利
- 法国
- 西班牙
- 俄罗斯
- 其他欧洲
亚太地区
- 中国
- 印度
- 日本
- ASEAN
- 澳洲
- 韩国
- 亚太其他地区
中东
- 海湾合作委员会国家
- 以色列
- 其他中东国家
非洲
- 南非
- 北非
- 中非

第七章竞争情势

热图分析
市占率分析（3x3矩阵）
公司简介
- Novartis
- BrainStorm Cell Therapeutics
- Corestem
- Q Therapeutics
- Helixmith
- Rapa Therapeutics
- Neuroplast
- StemCyte
- Ferrer Internacional
- Neuralstem
- Stemedica Cell Technologies
- Libella Gene Therapeutics
- Sangamo Therapeutics
- Hoffmann-La Roche
- LSio Gene Therapies
- Eli Lilly and Company
- NeuroGeneration
- Brain Neurotherapy Bio（AskBio）
- UniQure Biopharma

第八章分析师建议

机会
分析师观点
Coherent Opportunity Map

第九章各节

参考
调查方法

简介目录

Product Code: CMI4705

Gene And Cell Therapies Targeting Cns Disorders Market is estimated to be valued at USD 7.9 Bn in 2026 and is expected to reach USD 24.0 Bn by 2033, growing at a compound annual growth rate (CAGR) of 16.5% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 7.9 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	16.50%	2033 Value Projection:	USD 24.0 Bn

The market is at a transformational phase now, wherein the breakthroughs in molecular biology, genetics, and regenerative medicine are rewriting the treatment paradigms for CNS disorders. Traditionally, CNS diseases were managed by symptomatic treatments due to the intricacies in the brain and spinal cord along with the presence of the blood-brain barrier. Gene and cell therapies, however, can now circumvent such difficulties and allow targeted, disease-modifying, and potentially curative interventions.

Gene and cell therapies targeting CNS disorders cover a wide range of sophisticated therapeutic modalities, including viral vector-based gene replacement; gene silencing and editing technologies, including CRISPR; induced pluripotent stem cell-derived neural progenitors; and a variety of stem cell transplantation approaches. These therapies aim at correcting genetic defects, restoring neuronal function, replacing damaged cells, or modulating disease pathways at a molecular level. Neurogenetics and neurobiology have ignited and accelerated innovation in this field to date, making CNS disorders a viable and increasingly attractive therapeutic area.

The increasing incidence of neurodegenerative and neurological disorders such as Parkinson's disease, Alzheimer's disease, Huntington's disease, amyotrophic lateral sclerosis, and multiple sclerosis is a significant factor contributing to the growth of the market. With the rising geriatric population, advancements in diagnostic technologies, and greater awareness, the incidence of diseases is on a rise.

Market Dynamics

The market for gene and cell therapies targeting CNS disorders has been gaining significant traction due to the increasing prevalence of neurodegenerative diseases and the urgent unmet need for disease-modifying treatments. Such diseases as Parkinson's disease and Alzheimer's continue to increase in incidence throughout the world, placing a significant burden on the global health care system. This, in turn, increases the need for cutting-edge treatment solutions targeting the root cause of diseases instead of just relieving symptoms.

Technological advancements, another major driving factor which is anticipated to have a significant future impact on the development of the market is technological advancements. Advances in the technology area for viral vectors, ranging from adeno-associated virus (AAV) to lentiviral vectors, have resulted in enhanced delivery efficacy and safety associated with the vectors to the CNS. Similarly, advances in the area of stem cell research have resulted in the development of stem cells that are scalable and well-characterized from a functional perspective for transplantation purposes in the CNS.

The regulatory landscape is also evolving in favor of market expansion. Regulatory agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) are increasingly offering accelerated approval pathways, orphan drug designations, and regulatory guidance specifically tailored to advanced therapy medicinal products (ATMPs). These initiatives reduce development timelines and provide greater clarity for manufacturers, thereby encouraging investment and innovation in the CNS gene and cell therapy space.

Moreover, the incorporation of artificial intelligence and digital health technologies into CNS therapeutic development is improving the efficiency and rates of clinical trials. The use of machine learning approaches to stratify patients, digital biomarkers, and real-time disease monitoring solutions are allowing for more focused trials, measurement of endpoints, and post-market surveillance. This is significant, as it is in the realm of CNS disorders, where the complexity and slowing rate of progression have traditionally clouded clinical assessment.

Key Features of the Study

This report provides in-depth analysis of the Gene and Cell Therapies Targeting CNS Disorders market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2026-2033), considering 2025 as the base year.
It elucidates potential revenue opportunities across different segments such as therapy type, indication, and geography, and explains attractive investment proposition matrices for this market.
This study provides key insights about market drivers, restraints, opportunities, technological breakthroughs, regulatory developments, advanced-stage clinical trials, market trends, regional outlook, and competitive strategies adopted by key players.
It profiles key players in the gene and cell therapies targeting CNS disorders market based on the following parameters - company overview, therapeutic pipeline, technology platforms, key developments, and strategic initiatives.
Key companies covered as part of this study include Novartis, BrainStorm Cell Therapeutics, Corestem, Q Therapeutics, Helixmith, Rapa Therapeutics, Neuroplast, StemCyte, Ferrer Internacional, Neuralstem, Stemedica Cell Technologies, Libella Gene Therapeutics, Sangamo Therapeutics, Hoffmann-La Roche, LSio Gene Therapies, Eli Lilly and Company, NeuroGeneration, Brain Neurotherapy Bio (AskBio), and uniQure Biopharma
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The Gene and Cell Therapies Targeting CNS Disorders market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the Gene and Cell Therapies Targeting CNS Disorders Market

Market Segmentation

Therapy Type Insights (Revenue, USD Bn, 2026 - 2033)
- Gene Therapy
- Cell Therapy
Indication Insights (Revenue, USD Bn, 2026 - 2033)
- Alzheimer's Disease (AD)
- Huntington's Disease (HD)
- Parkinson's Disease (PD)
- Amyotrophic Lateral Sclerosis (ALS) & Motor Neuron Disease
- Multiple Sclerosis (MS)
- Adrenoleukodystrophy & Metachromatic Leukodystrophy
- Neuropathies
- Batten Disease (BD)
Regional Insights (Revenue, USD Bn, 2026 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
Key Players Insights
- Novartis
- BrainStorm Cell Therapeutics
- Corestem
- Q Therapeutics
- Helixmith
- Rapa Therapeutics
- Neuroplast
- StemCyte
- Ferrer Internacional
- Neuralstem
- Stemedica Cell Technologies
- Libella Gene Therapeutics
- Sangamo Therapeutics
- Hoffmann-La Roche
- LSio Gene Therapies
- Eli Lilly and Company
- NeuroGeneration
- Brain Neurotherapy Bio (AskBio)
- UniQure Biopharma

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snippet, By Therapy Type
- Market Snippet, By Indication
- Market Snippet, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- PEST Analysis
- PORTER's Five Forces Analysis
- Market Opportunities
- Regulatory Scenario
- Key Developments
- Industry Trend

4. Global Gene And Cell Therapies Targeting CNS Disorders Market, By Therapy Type, 2026-2033, (USD Bn)

Introduction
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Gene Therapy
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Cell Therapy
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends

5. Global Gene And Cell Therapies Targeting CNS Disorders Market, By Indication, 2026-2033, (USD Bn)

Introduction
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Alzheimer's Disease (AD)
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Huntington's Disease (HD)
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Parkinson's Disease (PD)
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Amyotrophic Lateral Sclerosis (ALS) & Motor Neuron Disease
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Multiple Sclerosis (MS)
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Adrenoleukodystrophy & Metachromatic Leukodystrophy
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Neuropathies
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Batten Disease (BD)
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends

6. Global Gene And Cell Therapies Targeting CNS Disorders Market, By Region, 2026-2033, (USD Bn)

Introduction
- Market Share Analysis, By Region, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, For Region, 2021 - 2033
North America
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Therapy Type, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Indication, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Country, 2026- 2033, (USD Bn)
  - U.S.
  - Canada
Latin America
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Therapy Type, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Indication, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Country, 2026- 2033, (USD Bn)
  - Brazil
  - Argentina
  - Mexico
  - Rest of Latin America
Europe
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Therapy Type, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Indication, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Country, 2026- 2033, (USD Bn)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Therapy Type, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Indication, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Country, 2026- 2033, (USD Bn)
  - China
  - India
  - Japan
  - ASEAN
  - Australia
  - South Korea
  - Rest of Asia Pacific
Middle East
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Therapy Type, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Indication, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Country, 2026- 2033, (USD Bn)
  - GCC Countries
  - Israel
  - Rest of Middle East
Africa
- Market Share Analysis, By Country/Region, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country/Region, 2021 - 2033
- Market Size and Forecast, By Therapy Type, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Indication, 2026- 2033, (USD Bn)
- Market Size and Forecast, By Country, 2026- 2033, (USD Bn)
  - South Africa
  - North Africa
  - Central Africa

7. Competitive Landscape

Heat Map Analysis
Market Share Analysis (3x3 Matrix)
Company Profiles
- Novartis
  - Company Overview
  - Product Type Portfolio
  - Recent Developments/Updates
- BrainStorm Cell Therapeutics
  - Company Overview
  - Product Type Portfolio
  - Recent Developments/Updates
- Corestem
  - Company Overview
  - Product Type Portfolio
  - Recent Developments/Updates
- Q Therapeutics
  - Company Overview
  - Product Type Portfolio
  - Recent Developments/Updates
- Helixmith
  - Company Overview
  - Product Type Portfolio
  - Recent Developments/Updates
- Rapa Therapeutics
  - Company Overview
  - Product Type Portfolio
  - Recent Developments/Updates
- Neuroplast
  - Company Overview
  - Product Type Portfolio
  - Recent Developments/Updates
- StemCyte
  - Company Overview
  - Product Type Portfolio
  - Recent Developments/Updates
- Ferrer Internacional
  - Company Overview
  - Product Type Portfolio
  - Recent Developments/Updates
- Neuralstem
  - Company Overview
  - Product Type Portfolio
  - Recent Developments/Updates
- Stemedica Cell Technologies
  - Company Overview
  - Product Type Portfolio
  - Recent Developments/Updates
- Libella Gene Therapeutics
  - Company Overview
  - Product Type Portfolio
  - Recent Developments/Updates
- Sangamo Therapeutics
  - Company Overview
  - Product Type Portfolio
  - Recent Developments/Updates
- Hoffmann-La Roche
  - Company Overview
  - Product Type Portfolio
  - Recent Developments/Updates
- LSio Gene Therapies
  - Company Overview
  - Product Type Portfolio
  - Recent Developments/Updates
- Eli Lilly and Company
  - Company Overview
  - Product Type Portfolio
  - Recent Developments/Updates
- NeuroGeneration
  - Company Overview
  - Product Type Portfolio
  - Recent Developments/Updates
- Brain Neurotherapy Bio (AskBio)
  - Company Overview
  - Product Type Portfolio
  - Recent Developments/Updates
- UniQure Biopharma
  - Company Overview
  - Product Type Portfolio
  - Recent Developments/Updates

8. Analyst Recommendation

Wheel of Fortune
Analyst View
Coherent Opportunity Map

9. Section

References
Research Methodology
About Us and Sales Contact

02-2729-4219

+886-2-2729-4219

License/价格

中枢神经系统疾病基因和细胞疗法市场：按治疗方法、适应症和地区划分

Gene and Cell Therapies Targeting CNS Disorders Market, By Therapy Type, By Indication, By Geography

市场动态